Proteus Digital Health

Andrew Thompson

Co-Founder, CEO

Andrew Thompson is Co-Founder, President and Chief Executive Officer of Proteus Digital Health. His vision for Digital Medicines is focused on expanding global access to care, dramatically increasing the value delivered by drugs, and creating a more sustainable model for innovation in pharmaceuticals that leverages the power of silicon, software and mobile devices. Thompson is a World Economic Forum Advisor, and a member of the selection committee for the World Economic ForumTechnology Pioneers. He also serves on the California Governor’s Health IT Security Advisory Board.

Passionate about bringing digital innovation to education, he is Co-Founder and Board Member of Summit Schools, a leading Charter School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie “Waiting for Superman”. He works in digital humanities innovation as a Member of the Stanford University Libraries Board and with Cambridge University. He is a Co-Founder of Parker Library Online – a leading destination for digital medieval studies.

Thompson has been active as a venture capital investor and entrepreneur in Silicon Valley for 30 years, completing several Fortune 100 M&A transactions and IPOs, and is a named author on 51 issued patents. He holds master’s degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB).

George Savage, M.D.

Co-Founder, Chief Medical Officer

George Savage is Chief Medical Officer and Co-Founder of Proteus Digital Health, and formerly the company’s vice president of research and development. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.

George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering.

George holds a B.S. in Biomedical Engineering from Boston University, an M.D. from Tufts University School of Medicine, and an M.B.A. from Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California. George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley.

Jeremy Frank

Senior Vice President, Digital Medicine

Dr. Jeremy Frank is Senior Vice President of Digital Medicine at Proteus Digital Health and is responsible for the formulation and development of digital medicines, as well as the technical operations, required by Proteus and its pharmaceutical partners.

Prior to his current role, Jeremy led all regulated product development efforts at Proteus (wearable sensors, ingestible sensors, medical software, and systems integration) and the launch of Proteus’ first commercial pilot, Helius, in the United Kingdom. Also, he was responsible for oversight of the qualification and scaling of the manufacturing operations of Proteus’ ingestible sensor.

Dr. Frank holds a Ph.D. in Mechanical Engineering from University of California, Berkeley, and a Bachelor’s degree in Mechanical Engineering from Stanford University.

Sean Handel

Senior Vice President Product

Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he led product initiatives from an early stage through the company’s IPO and subsequent acquisition by Athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.

Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.

David O'Reilly

Chief Platform Officer

David O’Reilly is Chief Platform Officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to healthcare and biotechnology companies at L.E.K. Consulting.

David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.

Olivia Ware

Senior Vice President, US Market and Franchise Development

Olivia Ware is a successful executive with over 20 years of experience in commercialization, pharmaceutical drug development and healthcare management. As SVP of US Market and Franchise Development, Olivia provides the strategy and guidance for global product launches and market assessments.

Most recently, Olivia worked as an independent consultant providing strategic support, management expertise and mentoring for companies across the biotech and pharmaceutical industries. Previously, Olivia served as Chief Commercial Officer at CytRX and held several senior leadership positions at Genentech. During her 13 years at Genentech, Olivia played key roles in the launch of several of the world’s largest revenue producing oncology drugs, including Rituxan®, Herceptin® and Avastin®.

Olivia has an MBA in Finance and Marketing, from the University of North Carolina at Chapel Hill and an A.B. from Davidson College.

Mark Zdeblick, Ph.D.

Co-Founder, Chief Technologist

Mark Zdeblick is Chief Technologist and Co-Founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the Chief Technology Officer for the optical switch group at K2 Optronics and served as founder and Chief Technology Officer of Redwood Microsystems.

Mark holds a B.S. in Civil Engineering and a B.A. in Architecture, both from the University of Illinois, and an M.S. in Aeronautics and Astronautics and Ph.D. in Electrical Engineering from Stanford University.

Jonathan Symonds, CBE

Chairman

Jonathan Symonds CBE was appointed as Deputy Group Chairman of HSBC Holdings plc in August 2018 and has been an independent non-executive Director since April 2014. He has extensive international financial and governance experience.

Mr. Symonds was previously Chairman of HSBC Bank plc, HSBC’s European subsidiary, which offers services to clients in the UK and Continental Europe.

Mr. Symonds was Chief Financial Officer of Novartis AG from 2009 to 2013. Before joining Novartis he was a Partner and Managing Director of Goldman Sachs; Chief Financial Officer of AstraZeneca plc; and a Partner at KPMG. His governance experience includes roles as non-executive Director and chair of the audit committees of Diageo plc and QinetiQ plc.

He is currently Chairman of Proteus Digital Health Inc. and of Genomics England Limited. He is also a non-executive director of Rubius Therapeutics, Inc.

Shumeet Banerji, Ph.D.

Board Member

Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. In 2013, Dr. Banerji retired from Booz & Company Inc. having served as its founding Chief Executive Officer.

Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally. He serves on the Board of HP, Inc., Reliance Industries Limited, Proteus Digital Health, Inc., Felix Pharmaceuticals Private Limited, and Tala Energy Private Limited.

Dr. Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.

Regina Benjamin, MD, MBA 

Board Member

Dr. Regina Benjamin is the Founder and CEO of BayouClinic in Bayou La Batre, Alabama, and the NOLA.com/Times Picayune Endowed Chair of Public Health Sciences at Xavier University of Louisiana.

She was the 18^th United States Surgeon General (2009 – 2013).

Dr. Benjamin serves on the boards of Kaiser Foundation Health Plan and Hospitals, the largest U.S. health managed care organization, and of Ascension, the world’s largest faith-based health system. She also serves on the boards of Diplomat, ConvaTec, CPSI, Next Level Health, and 98point6.

Robert Epstein, M.D., M.S.

Board Member

Dr. Robert Epstein is the cofounder and CEO of Epstein Health, LLC, a life science strategic consulting firm serving clients in the United States and Europe. Previously, Dr. Epstein served as president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.

Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and currently serves on the board of directors of Illumina, Fate Therapeutics, Veracyte, and Mindstrong Health.

He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.

Frank Fischer

Board Member

Frank Fischer has more than 25 years of senior management experience in the medical device industry.

The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.

Mr. Fischer continues to serve on the boards of several privately held medical device companies, in addition to serving on the board of trustees of Epilepsy Foundation of America, Rensselaer Polytechnic Institute, and Babson College.

Alan J. Levy, Ph.D.

Board Member

Dr. Alan Levy is a venture partner with Frazier Healthcare Partners and has over 30 years of senior management experience in the medical device industry.

Dr. Levy serves on the board of Intuitive Surgical, a publicly held company, in addition to Chrono Therapeutics, AbyRx, Signum Surgical, and the Center for Infectious Disease Research.

Ryan Schwarz

Board Member

Ryan Schwarz serves as managing director of NaviMed Capital and has over 30 years of investment and financial experience in healthcare. Previously, Mr. Schwarz led the healthcare investing practice for The Carlyle Group’s U.S. Venture & Growth Capital Group, specializing in medical devices, medical technology and healthcare information technology.

Mr. Schwarz currently serves on the boards of Lucent Health Solutions, Argos Health, and ORN Healthcare.

Charles Songhurst

Board Member

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.

Mr. Songhurst serves on the boards of Rigetti, SafeGraph, and CodeFights. Previously, he ran corporate strategy for Microsoft and focused on partnering and M&A.

Joseph R. Swedish

Board Member

Joseph R. Swedish is Executive Chairman of Anthem Inc., a Fortune 50 company, and the nation’s leading health benefits provider.

Formerly, Swedish served as CEO for several major integrated healthcare delivery systems, including Trinity Health, Colorado’s Centura Health, and Hospital Corporation of America.

Swedish serves on numerous corporate and industry association boards, and joined the Proteus Board of Directors in February 2018. He received his bachelor’s degree from the University of North Carolina at Charlotte and his master’s degree in health administration from Duke University.

Immanuel Thangaraj

Board Member

Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.

With more than 15 years of experience in operations and venture capital, he currently serves on the boards of Acura Pharmaceuticals, Kona Medical, Inc., and Serene LLC.